After acquiring Nutraceutix in October of 2016, Probi is rolling out a range of curated probiotic strains for gastrointestinal and immune support. Probi (Lund, Sweden), now a full-scale manufacturing company, is best known as the maker of LP299V, which, according to the company, is the world’s most researched strain of Lactobacillus plantarum. The company is now rolling out the following probiotic strains as part of the Probi brand: Probi Rhamnosus 6594 (Lactobacillus rhamnosus 6594), Probi Paracasei 13434 (Lactobacillus paracasei 13434), and Probi Plantarum 6595 (Lactobacillus plantarum 6595).
Both Probi Rhamnosus 6594 and Probi Paracasei 13434 ingredients are touted as beneficial to general health and supportive for immune defense. Probi Rhamnosus 6594 is specifically formulated for infants, while Probi Paracasei 13434 is intended for the general population. Probi Plantarum 6595 supports gastrointestinal and immune health and is said to reduce the risk of infection and inflammation, reduce gut permeability, and support immune defense in sensitive groups, such as athletes and the elderly.
Probi says it expects that the wider range of ingredients in the new line will make finding clinically documented strains even easier for companies in the probiotic market. According to Niklas Bjärum, president, Probi USA and Global Sales & Marketing, Probi Group: “It is extremely exciting to launch the new probiotic line—Probi Select. Through the integration of Nutraceutix, Probi has established a complete probiotic offering with the Probi Premium, Probi Select, and Probi LiveBac ranges. Probi is now a true ‘One stop shop’ for any consumer goods company wanting to drive their position in the probiotic market.”
The strains in Probi Select are clinically proven to survive to survive the passage through the gastrointestinal tract, according to the company, and thus benefit gut microbiota. Microbiota are essential to digestion, absorption of nutrients, and helping to balance the immune system, and helps protect against pathogens.